Trial Profile
The Impact of Obesity and Obesity Treatments on Breast Cancer: A Phase I Trial of Exemestane With Metformin and Rosiglitazone for Postmenopausal Obese Women With ER+ Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Exemestane (Primary) ; Rosiglitazone/metformin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 06 Aug 2012 Actual end date (1 Aug 2012) added as reported by ClinicalTrials.gov.
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jan 2012 Planned end date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.